Data updated: Mar 29, 2026
ADLARITY
DONEPEZIL HYDROCHLORIDE
Approved 2022-03-11
1
Indication
--
Phase 3 Trials
4
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2022-03-11
- Routes
- TRANSDERMAL
- Dosage Forms
- SYSTEM
ADLARITY Approval History
Loading approval history...
What ADLARITY Treats
1 FDA approvalsOriginally approved for its first indication in 2022 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ADLARITY FDA Label Details
ProADLARITY Patents & Exclusivity
Latest Patent: Aug 2038
Patents (44 active)
US10966936
Expires Aug 11, 2038
US10835499
Expires May 20, 2038
US11648214
Expires Sep 23, 2037
US11103463
Expires Jul 26, 2037
US10016372
Expires Jul 26, 2037
US10300025
Expires Jul 26, 2037
US10307379
Expires Jul 26, 2037
US9993466
Expires Jul 26, 2037
US11679086
Expires May 26, 2037
US12161767
Expires Dec 30, 2036
+ 34 more patents
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.